Is Indrapr.Medical overvalued or undervalued?

As of 28 July 2025, Indrapr.Medical's valuation grade has moved from fair to attractive, indicating a positive shift in its market standing. The company appears to be undervalued, supported by a PE ratio of 25.60, an EV to EBITDA of 15.74, and a PEG ratio of 0.86, which suggests that the stock is priced favorably relative to its growth potential.
In comparison with its peers, Indrapr.Medical's valuation metrics stand out. For instance, Apollo Hospitals, which is also rated attractive, has a significantly higher PE ratio of 73.3, while Max Healthcare is categorized as very expensive with a PE of 108.16. Despite recent stock performance showing a decline of 14.04% year-to-date against a 3.52% gain in the Sensex, the long-term growth of 656.73% over three years highlights the potential for recovery and growth in value.